78 results match your criteria: "Antoine Lacassagne Center[Affiliation]"
Oncologist
November 2024
Department of Supportive and Palliative Care, Institut Paoli-Camettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France.
Background: While the use of chemotherapy near the end of life (EOL) has been identified as a relevant criterion for assessing quality of cancer care and has been estimated as non-beneficial, a trend of aggressiveness in cancer care during the last period of life remains. Both patients' sociodemographic characteristics and physicians' practice setting are associated with this use. The role of patients' psychosocial characteristics has however been understudied.
View Article and Find Full Text PDFJ Geriatr Oncol
January 2025
Department of Radiation Oncology, CHU Saint-Etienne, Saint-Etienne, France; Department of Radiation Oncology, Institut Bergonié, Bordeaux, France.
Introduction: Chronological and functional aging complicates care in older patients, and therapeutic decisions need to consider individual needs to minimise morbidity and mortality. Therapeutic decisions should be guided by a multidisciplinary geriatric assessment, allowing a complete assessment of physical and functional performance. In this context, the GERABEL study aimed to orientate the irradiation strategy based on a detailed oncogeriatric assessment in women more than 70 years old with breast cancer.
View Article and Find Full Text PDFEur J Surg Oncol
October 2024
Université Paris Cité, ENT - Head and Neck Surgery Department, AP-HP, Hôpital Lariboisière, INSERM U1141, F-75010, Paris, France.
Objectives: The management of the facial nerve (FN) is a major issue in parotid cancer, especially when there is no preoperative facial palsy and FN invasion is discovered intraoperatively. The aim of this study was to assess the impact of FN resection in patients with parotid cancer abutting the FN, without pretreatment facial palsy, using a propensity score matching.
Materials And Methods: Data from all patients treated between 2009 and 2020 for a primary parotid cancer abutting or invading the FN but without pretreatment facial palsy were extracted from the national multicentric REFCOR database.
Oncologist
September 2024
Department of Gastroenterology, University Hospital Pontchaillou, Rennes 1 University, INSERM U1242 "Chemistry Oncogenesis Stress Signalling," Rennes, France.
Head Neck
September 2024
Department of Head and Neck Oncology, Gustave Roussy Institute, University Paris Saclay, Villejuif, France.
Circular pharyngolaryngectomy for oncologic resection requires a tubular reconstruction. Different options can be proposed to the patient: digestive free flap, fasciocutaneous flap, or musculocutaneous flap. The jejunum free flap is a tubular flap commonly used in esophageal and pharyngeal reconstruction with good functional outcomes and an acceptable rate of complications.
View Article and Find Full Text PDFAnn Oncol
September 2024
Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France. Electronic address:
Background: After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting of gemcitabine (GEM)-based regimens or the modified FOLFIRINOX (mFFX) regimen. While mFFX regimen has been shown to be more effective than GEM-based regimens, it is also associated with higher toxicity. Current treatment decisions are based on patient performance status rather than on the molecular characteristics of the tumor.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
July 2024
Department of Radiotherapy, Antoine Lacassagne Center, Nice, France.
Eur J Surg Oncol
December 2023
Department of Radiation Oncology, Bordeaux University Hospital, F33000, Bordeaux, France; Bordeaux University, na unit, UMR 6033, F-33000, Bordeaux, France; BRIC (BoRdeaux Institute of OnCology), UMR1312, INSERM, University of Bordeaux, F-33000, Bordeaux, France. Electronic address:
Objectives: Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive disease requiring multimodal treatment, and multiple new entities once included in the spectrum of SNUC, such as SWI/SNF-deficient carcinomas, are emerging. We aimed to provide new data regarding the role of chemotherapy and surgery and the prognostic factors of disease-free survival.
Methods: This study was based on data from the REFCOR database and included patients with SNUC treated with curative intent from 2007 to 2021 across 22 centres in France.
Metabolites
June 2023
Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E4320 TIRO-MATOs, Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Fréderic Joliot, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Faculté de Médecine, Côte d'Azur University, 28 Avenue de Valombrose, CEDEX 2, 06107 Nice, France.
Although it is the gold standard for assessing the malignancy of thyroid nodules (TNs) preoperatively, the cytological analysis of fine-needle aspiration cytology (FNAC) samples results in 20-30% of cases in indeterminate lesions (ITNs). As two-thirds of these lesions will appear benign after diagnostic surgery, improved preoperative diagnostic methods need to be developed. In this pilot study, we evaluate if the metabolomic profiles of liquid-based (CytoRich) FNAC samples of benign and malignant nodules can allow the molecular diagnosis of TNs.
View Article and Find Full Text PDFJ Clin Med
June 2023
Face and Neck Surgery Department, Antoine Lacassagne Center, 06100 Nice, France.
Background: Many classifications exist to select patients with "high-risk" head and neck cutaneous squamous cell carcinoma (HNCSCC).
Objective: To compare the performance of the Brigham and Women's Hospital (BWH) classification with the performance of the American Joint Committee on Cancer 8th Edition (AJCC8), the Union for International Cancer Control 8th Edition (UICC8), and the National Comprehensive Cancer Network (NCCN) classifications.
Methods: In this single-center retrospective study, HNCSCC resected in a tertiary care center were classified as "low-risk" or "high-risk" tumors according to the four classifications.
Curr Oncol
May 2023
Face and Neck University Institute, 31 Av. de Valombrose, 06103 Nice, France.
J Clin Med
September 2022
Department of Oral and Maxillo-Facial Surgery, Head and Neck Institute, 06100 Nice, France.
Background: When maxillary transversal expansion is needed, two protocols of treatment can be used: a maxillary orthodontic expansion followed by a classical bimaxillary osteotomy or a bimaxillary osteotomy with maxillary segmentation. The aim of this study was to assess the accuracy of segmented Le Fort I osteotomy using computer-aided orthognathic surgery and patient-specific titanium plates in patients who underwent a bimaxillary osteotomy for occlusal trouble with maxillary transversal insufficiencies. Methods: A virtual simulation of a Le Fort I osteotomy with maxillary segmentation, a sagittal split ramus osteotomy, and genioplasty (if needed) was conducted on a preoperative three-dimensional (3D) model of each patient’s skull using ProPlan CMF 3.
View Article and Find Full Text PDFJ Stomatol Oral Maxillofac Surg
February 2023
Oral and Maxillo-Facial Surgery Department, Head and Neck Institute of Nice, University Hospital of Nice, 31 avenue de Valombrose, 06100, Nice, France.
Int J Cancer
December 2022
Gastrointestinal Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris, France.
After failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR + PR + SD) and safety.
View Article and Find Full Text PDFSupport Care Cancer
October 2022
Department of Radiation Oncology, Centre François Baclesse, Caen, France.
Introduction: Despite reduction of xerostomia with intensity-modulated compared to conformal X-ray radiotherapy, radiation-induced dental complications continue to occur. Proton therapy is promising in head and neck cancers to further reduce radiation-induced side-effects, but the optimal dental management has not been defined.
Material And Methods: Dental management before proton therapy was assessed compared to intensity-modulated radiotherapy based on a bicentric experience, a literature review and illustrative cases.
Cancers (Basel)
March 2022
Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
Life Sci Alliance
July 2022
Centre de Recherche en Cancérologie de Lyon, INSERM U1052, Centre National de la Recherche Scientifique (CNRS) 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
The glucose-requiring hexosamine biosynthetic pathway (HBP), which produces UDP-N-acetylglucosamine for glycosylation reactions, promotes lung adenocarcinoma (LUAD) progression. However, lung tumor cells often reside in low-nutrient microenvironments, and whether the HBP is involved in the adaptation of LUAD to nutrient stress is unknown. Here, we show that the HBP and the coat complex II (COPII) play a key role in cell survival during glucose shortage.
View Article and Find Full Text PDFEur J Surg Oncol
June 2022
Department of Head and Neck Oncology, University Paris-Saclay, Gustave Roussy Institute, Villejuif, France. Electronic address:
Objective: We investigated the quality of life (QoL), functional, and oncological outcomes after robotic-assisted transoral or combined cervical-transoral salvage surgery for oropharyngeal carcinoma following radiotherapy.
Material And Methods: We performed a single tertiary referral center, prospective, observational cohort study of all consecutive patients who underwent salvage robotic-assisted surgery for oropharyngeal carcinoma between 2015 and 2021. The primary outcomes were quality of life assessments using the MDADI, EORTC-QLQC30, and EORTC-QLQH&N35.
Radiother Oncol
August 2021
Sorbonne Université, AP-HP, Pitié Salpêtrière Hospital, Department of Radiation Oncology, Paris, France; UMR_S 938, Centre de Recherche de Saint Antoine, Paris, France; APHP, Tenon Hospital, Department of Radiation Oncology, Paris, France.
Purpose: The aim of this study is to correlate locoregional relapse with radiation therapy volumes in patients with rectal cancer treated with neoadjuvant chemoradiation in the ACCORD 12/0405-PRODIGE 02 trial.
Patients And Methods: We identified patients who had a locoregional relapse included in ACCORD 12's database. We studied their clinical, radiological, and dosimetric data to analyze the dose received by the area of relapse.
J Clin Oncol
December 2020
Head Neck Surgery Department, Montpellier University Hospital Center, Montpellier, France.
Br J Radiol
December 2020
Université de Lorraine, Vandœuvre-lès-Nancy, France.
Objectives: This prospective, observational, non-randomized multicentric study was conducted to compare efficiency and toxicity using different modalities of stereotactic body radiation therapy (SBRT) in early-stage peripheral non-small cell lung cancer (NSCLC).
Methods: From 9 April to 11 December, 106 patients were treated according to the local equipment availability for peripheral NSCLC with SBRT: 68 by linear accelerator equipped for SBRT and 38 by Cyberknife. Multivariate analysis and propensity score analysis using Inverse Probability Treatment Weighting (IPTW) were undertaken in an effort to adjust for potential bias due to non-randomization.
Int J Mol Sci
September 2020
INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Docetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous cell carcinoma (SCCA), as demonstrated by the Epitopes-HPV02 study results. Here, we analyzed the impact of DCF regimen and the prognostic value of adaptive immune responses and immunosuppressive cells in SCCA patients included in two prospective studies (Epitopes-HPV01 and HPV02). The presence of T-cell responses against Human papillomavirus (HPV)16-E6/E7 and anti-telomerase (hTERT)-antigens was measured by IFNᵧ-ELISpot.
View Article and Find Full Text PDFCancers (Basel)
July 2020
Department of Biochemistry, CHU Nantes, 44093 Nantes, France.
Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was to determine whether the detection of ctDNA, based on the identification of and mutations before systemic treatment initiation, was associated with the prognosis of metastatic melanoma. In total, 68 or -mutated stage IV or unresectable stage III metastatic cutaneous melanoma patients were included and tested for the presence of and mutations in circulating DNA before treatment initiation, using the Cobas BRAF/NRAS Mutation Test (Roche).
View Article and Find Full Text PDFSci Rep
July 2020
Oncology Department, Centre Léon Bérard, Lyon, France.
Benefits of physical activity are widely demonstrated for early stage cancers but few studies have focused on metastatic disease. The purpose of this study was to determine the impact of physical activity on survival in patients with metastatic breast cancer. We conducted a secondary analysis of the national, multicentric, non-randomized, prospective cohort SNPs to Risk of Metastasis (StoRM) study.
View Article and Find Full Text PDFLung Cancer
July 2020
Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d'Azur, 30 avenue de la voie romaine, 06000, Nice, France; Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, University Côte d'Azur, 30 avenue de la voie romaine, 06000, Nice, France; FHU OncoAge, Pasteur Hospital, University Côte d'Azur, 30 avenue de la voie romaine, 06000, Nice, France; IRCAN Inserm 1081/CNRS 7283, Antoine Lacassagne Center, avenue de valombrose, 06002, Nice, France. Electronic address:
Introduction: International guidelines recommend BRAF mutational status assessment in treatment-naive advanced non-squamous non-small cell lung carcinoma (NSCLC) patients since the presence of a BRAFV600 mutation enables specific BRAF inhibitor treatment. For this purpose, the mutational status needs to be obtained in 10 working days. Herein, we prospectively evaluated the feasibility of systematic assessment of the BRAF status using immunohistochemistry (IHC) in a single institution (LPCE, Nice) at baseline for NSCLC diagnosed.
View Article and Find Full Text PDF